Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection is a neuromuscular blocking agent
Rocuronium Bromide Injection is a neuromuscular blocking agent
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
he product will be launched shortly in the US market.
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
This combination medicine is used to treat high blood pressure (hypertension).
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Subscribe To Our Newsletter & Stay Updated